Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Terri Wrin

Showing results (41-50 of 106) with videos related to

Pageof 11
Sort By:
Journal of Virology|December 14, 2011
Longitudinal analysis of early HIV-1-specific neutralizing activity in an elite neutralizer and in five patients who developed cross-reactive neutralizing activityZelda Euler, Tom L G M van den Kerkhof, Marit J van Gils, et al.
Frontiers in Immunology|June 4, 2019
Unusual Cysteine Content in V1 Region of gp120 From an Elite Suppressor That Produces Broadly Neutralizing AntibodiesJennie M Hutchinson, Kathryn A Mesa, David L Alexander, et al.
Antimicrobial Agents and Chemotherapy|November 23, 2006
Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropismJeannette M Whitcomb, Wei Huang, Signe Fransen, et al.
AIDS Research and Human Retroviruses|January 25, 2005
Longitudinal assessment of immune response and viral characteristics in HIV-infected patients with prolonged CD4(+)/viral load discordanceSusan S Kaplan, Guido Ferrari, Terri Wrin, et al.
AIDS (London, England)|July 29, 2004
Persistence of primary drug resistance among recently HIV-1 infected adultsJason D Barbour, Frederick M Hecht, Terri Wrin, et al.
Molecular Therapy. Methods & Clinical Development|July 18, 2024
Global seroprevalence of neutralizing antibodies against adeno-associated virus serotypes used for human gene therapiesAmit Chhabra, George Bashirians, Christos J Petropoulos, et al.
Journal of Virology|May 30, 2006
Neutralizing antibody responses against autologous and heterologous viruses in acute versus chronic human immunodeficiency virus (HIV) infection: evidence for a constraint on the ability of HIV to completely evade neutralizing antibody responsesSteven G Deeks, Becky Schweighardt, Terri Wrin, et al.
Journal of Virology|August 31, 2012
Sequences in glycoprotein gp41, the CD4 binding site, and the V2 domain regulate sensitivity and resistance of HIV-1 to broadly neutralizing antibodiesSara M O'Rourke, Becky Schweighardt, Pham Phung, et al.
Plos One|September 17, 2013
Chimeric rhinoviruses displaying MPER epitopes elicit anti-HIV neutralizing responsesGuohua Yi, Mauro Lapelosa, Rachel Bradley, et al.
Plos One|October 12, 2013
Correction: Chimeric Rhinoviruses Displaying MPER Epitopes Elicit Anti-HIV Neutralizing ResponsesGuohua Yi, Mauro Lapelosa, Rachel Bradley, et al.
Pageof 11

Showing results (41-50 of 106) with videos related to

Sort By:
Pageof 11
Journal of Virology|December 14, 2011
Longitudinal analysis of early HIV-1-specific neutralizing activity in an elite neutralizer and in five patients who developed cross-reactive neutralizing activityZelda Euler, Tom L G M van den Kerkhof, Marit J van Gils, et al.
Frontiers in Immunology|June 4, 2019
Unusual Cysteine Content in V1 Region of gp120 From an Elite Suppressor That Produces Broadly Neutralizing AntibodiesJennie M Hutchinson, Kathryn A Mesa, David L Alexander, et al.
Antimicrobial Agents and Chemotherapy|November 23, 2006
Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropismJeannette M Whitcomb, Wei Huang, Signe Fransen, et al.
AIDS Research and Human Retroviruses|January 25, 2005
Longitudinal assessment of immune response and viral characteristics in HIV-infected patients with prolonged CD4(+)/viral load discordanceSusan S Kaplan, Guido Ferrari, Terri Wrin, et al.
AIDS (London, England)|July 29, 2004
Persistence of primary drug resistance among recently HIV-1 infected adultsJason D Barbour, Frederick M Hecht, Terri Wrin, et al.
Molecular Therapy. Methods & Clinical Development|July 18, 2024
Global seroprevalence of neutralizing antibodies against adeno-associated virus serotypes used for human gene therapiesAmit Chhabra, George Bashirians, Christos J Petropoulos, et al.
Journal of Virology|May 30, 2006
Neutralizing antibody responses against autologous and heterologous viruses in acute versus chronic human immunodeficiency virus (HIV) infection: evidence for a constraint on the ability of HIV to completely evade neutralizing antibody responsesSteven G Deeks, Becky Schweighardt, Terri Wrin, et al.
Journal of Virology|August 31, 2012
Sequences in glycoprotein gp41, the CD4 binding site, and the V2 domain regulate sensitivity and resistance of HIV-1 to broadly neutralizing antibodiesSara M O'Rourke, Becky Schweighardt, Pham Phung, et al.
Plos One|September 17, 2013
Chimeric rhinoviruses displaying MPER epitopes elicit anti-HIV neutralizing responsesGuohua Yi, Mauro Lapelosa, Rachel Bradley, et al.
Plos One|October 12, 2013
Correction: Chimeric Rhinoviruses Displaying MPER Epitopes Elicit Anti-HIV Neutralizing ResponsesGuohua Yi, Mauro Lapelosa, Rachel Bradley, et al.
Pageof 11